Genetic diversity and pathogenic variants as possible predictors of severity in a French sample of nonsyndromic heritable thoracic aortic aneurysms and dissections (nshTAAD).


Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
09 2019
Historique:
received: 21 09 2018
accepted: 14 01 2019
pubmed: 12 2 2019
medline: 6 2 2020
entrez: 12 2 2019
Statut: ppublish

Résumé

Heritable thoracic aortic aneurysms and dissections (hTAAD) are life-threatening complications of well-known syndromic diseases or underdiagnosed nonsyndromic heritable forms (nshTAAD). Both have an autosomal dominant transmission and are genetically heterogeneous. Our objective was to describe the relevance of molecular diagnosis in these patients and the contribution of each gene in nshTAAD. Two hundred twenty-six consecutive nshTAAD probands, either young (<45 years) sporadic or familial cases were included. A next-generation sequencing capture panel comprising 23 known disease-causing genes was performed. Class 4 or 5 variants were identified in 18% of the nshTAAD probands, while class 3 variants were found in 10% of them. The yield in familial cases was greater than in sporadic cases. SMAD3 and FBN1 genes were the major disease-causing genes. Unexpectedly, no premature termination codon variant was identified in the FBN1 gene. Furthermore, we report for the first time that aortic dissection or surgery occurred significantly more often and earlier in probands with a class 4 or 5 pathogenic variant. This study indicates that genetic screening using NGS is efficient in young and familial nshTAAD. The presence of a pathogenic variant has a possible predictive value, which needs to be further investigated because it may influence care.

Identifiants

pubmed: 30739908
doi: 10.1038/s41436-019-0444-y
pii: S1098-3600(21)04992-3
doi:

Substances chimiques

Codon, Nonsense 0
FBN1 protein, human 0
Fibrillin-1 0
SMAD3 protein, human 0
Smad3 Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2015-2024

Auteurs

Pauline Arnaud (P)

Hôpital Bichat, Département de Génétique, Assistance Publique-Hôpitaux de Paris, Paris, France.
LVTS, INSERM U1148, Hôpital Bichat, Université Paris Diderot, Paris, France.
Hôpital Bichat, Centre de Référence Maladies Rares, Syndrome de Marfan et pathologies apparentées, Assistance Publique-Hôpitaux de Paris, Paris, France.

Nadine Hanna (N)

Hôpital Bichat, Département de Génétique, Assistance Publique-Hôpitaux de Paris, Paris, France.
LVTS, INSERM U1148, Hôpital Bichat, Université Paris Diderot, Paris, France.
Hôpital Bichat, Centre de Référence Maladies Rares, Syndrome de Marfan et pathologies apparentées, Assistance Publique-Hôpitaux de Paris, Paris, France.

Louise Benarroch (L)

LVTS, INSERM U1148, Hôpital Bichat, Université Paris Diderot, Paris, France.

Mélodie Aubart (M)

LVTS, INSERM U1148, Hôpital Bichat, Université Paris Diderot, Paris, France.

Laurence Bal (L)

Hôpital Timone Adultes, Service de Chirurgie vasculaire, Assistance Publique-Hôpitaux de Marseille, Marseille, France.

Patrice Bouvagnet (P)

Hospices Civils de Lyon, Hôpital Louis Pradel, Service de Cardiologie Pédiatrique et Congénitale adulte, Centre Hospitalier Universitaire de Lyon, Bron, France.

Tiffany Busa (T)

Hôpital Timone Enfants, Service de Génétique clinique, Département de Génétique Médicale, Assistance Publique-Hôpitaux de Marseille, Marseille, France.

Yves Dulac (Y)

Hôpital des Enfants, Service de Cardiologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

Sophie Dupuis-Girod (S)

Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Service de Génétique Clinique, Centre Hospitalier Universitaire de Lyon, Bron, France.

Thomas Edouard (T)

Hôpital des Enfants, Service de Pédiatrie - Endocrinologie, Génétique et Gynécologie Médicale, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

Laurence Faivre (L)

Centre de Génétique et FHU TRANSLAD, Centre Hospitalier Universitaire Dijon, Dijon, France.

Laurent Gouya (L)

Hôpital Bichat, Centre de Référence Maladies Rares, Syndrome de Marfan et pathologies apparentées, Assistance Publique-Hôpitaux de Paris, Paris, France.

Didier Lacombe (D)

GH Pellegrin, Service de Génétique Médicale, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
INSERM U1211, Université de Bordeaux, Bordeaux, France.

Maud Langeois (M)

Hôpital Bichat, Centre de Référence Maladies Rares, Syndrome de Marfan et pathologies apparentées, Assistance Publique-Hôpitaux de Paris, Paris, France.

Bruno Leheup (B)

Hôpital de Brabois, Service de Génétique Clinique, Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-, Nancy, France.

Olivier Milleron (O)

Hôpital Bichat, Centre de Référence Maladies Rares, Syndrome de Marfan et pathologies apparentées, Assistance Publique-Hôpitaux de Paris, Paris, France.

Sophie Naudion (S)

GH Pellegrin, Service de Génétique Médicale, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.

Sylvie Odent (S)

Hôpital Sud, Service de Génétique Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.

Maria Tchitchinadze (M)

Hôpital Bichat, Centre de Référence Maladies Rares, Syndrome de Marfan et pathologies apparentées, Assistance Publique-Hôpitaux de Paris, Paris, France.

Jacques Ropers (J)

Unité de Recherche Clinique HU Paris Île-de-France Ouest, Boulogne, France.

Guillaume Jondeau (G)

LVTS, INSERM U1148, Hôpital Bichat, Université Paris Diderot, Paris, France.
Hôpital Bichat, Centre de Référence Maladies Rares, Syndrome de Marfan et pathologies apparentées, Assistance Publique-Hôpitaux de Paris, Paris, France.

Catherine Boileau (C)

Hôpital Bichat, Département de Génétique, Assistance Publique-Hôpitaux de Paris, Paris, France. catherine.boileau@inserm.fr.
LVTS, INSERM U1148, Hôpital Bichat, Université Paris Diderot, Paris, France. catherine.boileau@inserm.fr.
Hôpital Bichat, Centre de Référence Maladies Rares, Syndrome de Marfan et pathologies apparentées, Assistance Publique-Hôpitaux de Paris, Paris, France. catherine.boileau@inserm.fr.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH